Cadila Pharma unveils antihistamine drug Bilastine in India

The Bilastine has an advantage over other molecules available in the category, as the faster onset of action, non-drowsy, cardiac safe. Cadila Pharmaceutical's product under the brand name Bilacad also ensures better safety and efficacy.

Published On 2020-06-28 07:45 GMT   |   Update On 2020-06-29 07:45 GMT

Ahmedabad: Cadila Pharmaceuticals Limited has recently announced the launch of Bilastine syrup (30 ml) and Bilastine tablets in the strength of 20mg. It is indicated that Bilastine, an antihistamine drug is used in the treatment of allergic rhinitis.Bilastine is an antihistamine which addresses the current gap in the treatment of Allergic Rhinitis and meets the expectations of doctors to...

Login or Register to read the full article

Ahmedabad: Cadila Pharmaceuticals Limited has recently announced the launch of Bilastine syrup (30 ml) and Bilastine tablets in the strength of 20mg. It is indicated that Bilastine, an antihistamine drug is used in the treatment of allergic rhinitis.

Bilastine is an antihistamine which addresses the current gap in the treatment of Allergic Rhinitis and meets the expectations of doctors to treat their allergic rhinitis patients. The Bilastine has an advantage over other molecules available in the category, as the faster onset of action, non-drowsy, cardiac safe. Cadila Pharmaceutical's product under the brand name Bilacad also ensures better safety and efficacy.

India has seen a growth in the number of cases of allergic rhinitis induced due to tobacco smoke, exposure to air pollutants, vehicular pollution, and other air pollution.

Moreover, as per a recent study published in Lung India, 65% of the Indian allergic rhinitis patients also suffer from Asthma. Improved control of nasal allergies can help gain better control on Asthma.

Cadila Pharmaceuticals Ltd. has recently concluded USFDA inspection successfully in February 2020. 

Read also: Zydus Cadila gets USFDA nod to antihistamine Meclizine Hydrochloride Tablets

Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News